Medscape4d
Safe and Effective Outpatient Treatment of Adults with Chemotherapy-Induced Neutropenic Fever
Patients with neutropenic fever represent a heterogeneous population. Evaluation and assessment of the risk of complications associated with infection are the first steps in appropriate management.
Cure Today6d
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
Medscape2d
Safe and Effective Outpatient Treatment of Adults with Chemotherapy-Induced Neutropenic Fever
The accepted standard for treatment of neutropenic fever remains inpatient therapy with i.v. broad-spectrum antibiotics. However, some centers have had success treating selected low-risk patients ...
Le Lézard1h
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...
Cure Today6d
Opdivo Plus Chemo May Be Effective and Safe in Older Patients with cHL
Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.
Le Lézard6d
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...